No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NVS240621P105000
- 0.75
- +0.20+36.36%
15min DelayClose Jun 14 16:00 ET
0.75High0.45Low
0.50Open0.55Pre Close39 Volume2.21K Open Interest105.00Strike Price2.42KTurnover18.24%IV1.39%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.75Extrinsic Value100Contract SizeAmericanOptions Type-0.3673Delta0.1544Gamma169.15Leverage Ratio-0.0765Theta-0.0057Rho-62.13Eff Leverage0.0505Vega
Intraday
- 5D
- 1D
News
U.S. Drug Shortages Worsen to Reach a Decade High: Report
EU to Require Additional Cancer Risk Labeling on CAR T Therapies
Express News | World Health Organization Chief: At This Time, Who Continues To Assess Risk To Public Health From H5n1 As Low
Is Novartis AG (NYSE:NVS) Investors' Favorite International Dividend Stock?
Top Gap Ups and Downs on Friday: INFY, SHW, WIT and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Abu Dhabi, Novartis to Collaborate on Genomics Research for Cancer Therapy
Abu Dhabi's Department of Health and Novartis (NOVN.SW) unit Novartis Middle East FZE signed a memorandum of understanding for a partnership aimed at advancing genomics research in oncology and other
Comments
Keep an eye on these recently announced M&As: 👀
$Merck & Co(MRK.US$ to acquire EyeBio
$Biogen(BIIB.US$ to acquire HI-Bio™
$Johnson & Johnson(JNJ.US$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals(RPHM.US$
$Novartis AG(NVS.US$ to acquire Mariana Oncology
What companies will be next? 🤔
$Merck & Co(MRK.US$ to acquire EyeBio
$Biogen(BIIB.US$ to acquire HI-Bio™
$Johnson & Johnson(JNJ.US$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals(RPHM.US$
$Novartis AG(NVS.US$ to acquire Mariana Oncology
What companies will be next? 🤔
3
$Esperion Therapeutics(ESPR.US$ Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, have positioned it as defininte acquistion target for larger pharmaceutical companies. Esperion's drugs NEXLIZET and NEXLETOL now have primary prevention labels, NEXLIZET will soon become the drug of choice over a PCSK9 inhibitor says Texas based HeartPlace leading Cardio...
12
Stories you might have missed ![]()
Singapore’s private home sales down nearly half in February; 149 condos sold amid holiday lull
DEVELOPERS in Singapore sold 149 private homes in February, 47 per cent fewer than the 281 units moved in January, data released on Friday (Mar 15) by the Urban Redevelopment Authority showed.
Novartis invests US$256 million to expand Singapore plant
SWISS biopharma giant Novartis has invested US$256 million to expand its biopharm...
Singapore’s private home sales down nearly half in February; 149 condos sold amid holiday lull
DEVELOPERS in Singapore sold 149 private homes in February, 47 per cent fewer than the 281 units moved in January, data released on Friday (Mar 15) by the Urban Redevelopment Authority showed.
Novartis invests US$256 million to expand Singapore plant
SWISS biopharma giant Novartis has invested US$256 million to expand its biopharm...
7
Google's disappointing ad sales growth and AMD's lower revenue guidance have hurt investor sentiment, causing their shares to drop. Byron Allen's offer to acquire Paramount Global is seen as beneficial for shareholders, boosting its share price. Novartis AG's lower Q4 earnings and adjusted mid-term guidance have led to a share price decline.
JPMorgan analysts predict a strong uptake for Novartis's various treatments to boost the company's top line, with cost savings from restructuring aiding the bottom line. Morgan Stanley analysts note Novartis's need for external innovation to meet long-term growth ambitions.
Read more